CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02167594
NCT02167594Phase 1Completed
CompareCT.gov

18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers

Avid Radiopharmaceuticals·interventional·Posted Jun 19, 2014·Updated Aug 28, 2020

In Brief

A Phase 1 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Progressive Supranuclear Palsy and Corticobasal Degeneration. Completed, enrolled 29 participants across 5 sites.

Detailed Summary

This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Supranuclear Palsy, Corticobasal Degeneration
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 19, 2014
Enrollment StartAug 12, 2014
Primary CompletionJul 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.0 years ago

Interventions

Flortaucipir F18drug

IV injection, 370 megabecquerel (MBq) (10 mCi)

Brain PET scanprocedure

positron emission tomography (PET) scan of the brain 75-105 minutes post-injection